Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Efficacy endpoints

From: Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

Endpoint Results
Median time to progression second-line trastuzumab-based therapy (months) 7 (95% CI 5.74-8.26)
Median time to progression first-line trastuzumab-based therapy (months) 8 (95% CI 6.26-9.74)
Overall survival (months) 43 (95% CI 37,92-48.09)
Response rate second-line trastuzumab-based therapy (%) 30.9%
Complete response (%) 7.2%
Partial response (%) 23.7%
Response rate first-line trastuzumab-based therapy (%) 44.3%
Complete response (%) 9.3%
Partial response (%) 35.1%
Clinical Benefit second-line trastuzumab-based therapy (%) 66%
Clinical Benefit first-line trastuzumab-based therapy (%) 83.5%
Time to development of brain metastases (months) 21 (95% CI 13.86-28.14)
Overall survival after treatment for brain metastases (months) 10 (95% CI 4.53-15.47)
Drop of left ventricular ejection fraction (LVEF) > 10% (n=) 3
Symptomatic congestive heart failure (n=) 2